Quizartinib and High-dose Ara-C Plus Mitoxantrone in Relapsed/Refractory AML With FLT3-ITD

Clinical trial NCT03989713 · TERMINATED

Trial details

NCT number: NCT03989713
Sponsor: Prof. Dr. Richard F Schlenk
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed After First Line Treatment)

Start date: 2020-07-17
Primary completion: 2022-09-11
Enrollment: 11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.